WebOct 13, 2024 · Plaintiffs, who had launched a proxy contest in July 2024 to replace five of six incumbent directors at the Company’s 2024 annual meeting, argued that the board wrongfully rejected the nomination notice, triggering enhanced scrutiny under Blasius Indus., Inc. v. Atlas Corp., 564 A.2d 651 (Del. Ch. 1988). WebNov 24, 2024 · CytoDyn has filed with the SEC a definitive proxy statement and associated BLUE proxy card in connection with the solicitation of proxies for the Company’s 2024 …
News / Events :: CytoDyn Inc. (CYDY)
WebNov 25, 2024 · FEATURED Music Licensing, Inc. (OTC:SONG) Announces Groundbreaking Research and Plans to Develop Proprietary AI Music Technology • Apr 10, 2024 8:30 AM. ILUS Files Its 2024 Annual Report With the SEC, Confirming a 595% Revenue Increase Over 2024 • ILUS • Apr 10, 2024 8:04 AM. M2Bio Appoints Ze-ev Krein as Chairman of … WebApr 10, 2024 · Interesting passage in the 10Q. Probably gives an idea of what to expect tomorrow as far as the clinical work relatively near term: The Company’s efforts are currently primarily directed toward obtaining the removal of the partial clinical hold on its HIV program, preparation for and development of a Phase 2b/3 NASH clinical trial protocol, research … bipv curtain wall
CytoDyn Reminds Stockholders to Register 24 hours before …
WebJul 30, 2024 · Annual Meeting. The Board of Directors (the 'Board') of CytoDyn Inc. (the 'Company') has determined that the Company's 2024 annual meeting of stockholders (the '2024 Annual Meeting') will be held virtually at 8:00 a.m. Pacific Time on October 28, 2024. WebApr 11, 2024 · CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel … CytoDyn is a publicly traded late stage biotechnology company developing … WebApr 13, 2024 · Following the Company's 2024 Annual Meeting of Stockholders, the Board of Directors declared a quarterly dividend of 70 cents per share, payable June 9, 2024, to … bipv and double skin facade